Specimens

标本核心支持加州大学可持续发展委员会SPOTRIAS站点和SPOTRIAS国家网络的所有活动， 通过安排收集、储存和运送急性中风、短暂性脑缺血发作和 模拟条件。具体目标1继续我们获取、加工和储存血液的常规程序 来自多个时间点的急性患者的样本。我们已经建立了抽血协议 我们合作地点的急诊科、重症监护病房和普通病房。一批 程序确保所有SPOTRIAS标本的质量处理和标签。具体目标2建议 衍生一组血清标志物，旨在帮助预测短暂性脑缺血后的未来缺血事件 攻击(TIA)。尝试将TIA患者分为高风险组和低风险组是很重要的，无论是 ABCD2模型或血清生物标记物已被用于这一目的的前景验证。我们将派生出一个 多标记面板，显示良好的预测价值，以估计后续中风风险，然后 将衍生生物标记物面板的预测值与ABCD2方法进行比较。同意后，血液 在TIA患者入院后，将尽快抽取样本。血液将被运往Biosite， Inc.，用于化验。主要终点将是短暂性脑缺血发作后90天的新卒中发生率。次要的 终点将是90天NIHSS和修改后的Rankin量表。我们还将计算ABCD2预测 对每个病人来说。我们期望临床评估，ABCD2，能够合理地预测随后的中风风险 预测性价值。我们希望能够衍生出一个多标记的生物标记物小组，它也具有 ROC曲线的合理AUC。我们将确定哪一种方法优于另一种方法。

The specimen core supports all activities of the UCSD SPOTRIAS site, and the SPOTRIAS national network, by arranging for the collection, storage, and shipment of specimens from patients with acute stroke, TIA, and mimic conditions. Specific Aim 1 continues our routine procedures to obtain, process, and store blood specimens from acute patients at multiple time points. We have established blood-drawing protocols in the emergency departments, intensive care units, and general wards at our collaborating sites. A number of procedures ensure quality handling and labeling of all SPOTRIAS specimens. Specific Aim 2 proposes to derive a panel of serum markers designed to help predict future ischemic events after transient ischemic attack (TIA). It is important to attempt to stratify TIA patients into high- and low-risk groups, and neither the ABCD2 model nor serum biomarkers has been prospectivelv validated for this purpose. We will derive a multi-marker panel that shows good predictive value for estimating subsequent stroke risk, and then compare the predictive value of the derived biomarker panel to the ABCD2 method. After consent, blood samples will be drawn as soon as practical after admission of TIA patients. Blood will be shipped to Biosite, Inc., for assay. The primary endpoint will be the 90-day incidence of new stroke after TIA. Secondary endpoints will be the 90-day NIHSS and modified Rankin Scale. We will also compute an ABCD2 prediction for each patient. We expect the clinical estimate, ABCD2, to predict subsequent stroke risk with reasonable predictive value. We expect to be able to derive a multi-marker panel of biomarkers that also has a reasonable AUC for the ROC curve. We will determine whether either method is superior to the other.